---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-029974"
form_type: "8-K"
ticker: "CTSO"
cik: "0001175151"
company_name: "Cytosorbents Corp"
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:31:35.126886+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CytoSorbents Q4 product rev $9.2M (+25% YoY); FY rev $35.6M (+15%); expects FDA decision 2025

## Summary
- Q4 product revenue $9.2M (+25% YoY); product gross margin 71%; operating loss improved 61% to $3.7M.
- Adjusted net loss improved 78% to $1.7M ($0.03 per share) vs $7.8M loss in Q4 2023.
- Full year product revenue $35.6M (+15%); net loss $20.7M ($0.38 per share); adjusted net loss $12.7M ($0.23 per share).
- Cash $9.8M at Dec 31; pro forma $17M after $7.3M rights offering net proceeds.
- Expects DrugSorb-ATR FDA & Health Canada decisions in 2025; Q1 2025 product sales to decline due to Germany restructure.

## SEC filing metadata
- accession: 0001104659-25-029974
- form_type: 8-K
- ticker: CTSO
- cik: 0001175151
- company_name: Cytosorbents Corp
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175151/000110465925029974/0001104659-25-029974-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175151/000110465925029974/tm2510844d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-029974
- JSON: https://secwatch.observer/filing/0001104659-25-029974.json
- Plain text: https://secwatch.observer/filing/0001104659-25-029974.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.